DC-2009-1002
DC-2009-1002. Consent for publication All the subjects for whom the clinical data were published completed a written informed consent. Competing interests The authors declare that they have no competing interests?related to this study. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Contributor Information Pierre H. blood samples, collected from the patients suspected of HGA, was found positive for by PCR. Acute and late sera from 138 of these 575 individuals were available. These combined sera were tested for IgM and IgG antibodies against the GlpQ antigen. A total of 14 from 138 individuals had GSK J1 a minumum of one positive parameter (i.e. anti-GlpQ IgG and/or IgM). One individual seroconverted for IgG, and three experienced isolated IgM in the acute serum. These three individuals were treated with doxycycline which could have prevented seroconversion. After critiquing medical data along with other biological checks performed, co-exposure among different microorganisms vectored by ticks or serological cross-reactivity could not be ruled out in these different instances. One individual had prolonged IgG, which strongly suggests earlier exposure to through tick bites in Alsace. We present serological data for possible exposure or illness of individuals with fever after tick bite. Future studies should determine the incidence, medical program and burden of this growing tick-borne disease in other parts of Western Europe. disease, GlpQ, Tick-borne diseases, Post-tick bite fever Background is currently the only species belonging to the relapsing fever group that is transmitted by ticks of the complex [1]. In 2011, the first series of individuals with febrile diseases caused by were explained in Russia [2] and later on in the USA [3C5]. The disease was designated as disease (BMD) or hard tick-borne relapsing fever and should be the object of differential analysis of human being granulocytic anaplasmosis (HGA) [3]. In parallel, instances of meningoencephalitis caused by in highly immunocompromised individuals, receiving B-cell depleting therapy have been explained since 2013 and one case was reported in an apparently immunocompetent patient [6C9]. In central Europe, only one blood sample has been found to be PCR-positive so far, albeit inside a person without symptoms [10]. However, serological evidence for exposure was found among forestry workers [11]. More recently, a case of post-tick bite febrile syndrome has been reported in western Europe, and serological results suggested that was the causative agent of the individuals symptoms [12]. The Alsace region of France is an area with a high denseness of [13C15]. Since was found in ticks in France and surrounding countries [16C18], we targeted to study the prevalence of in individuals suspected of post-tick bite febrile illness in northeastern France using direct and indirect diagnostic tools, as well as by measuring illness rates in ticks GSK J1 collected in the same region. Methods Study area and tick collection Alsace is definitely GSK J1 a region located in the northeastern part of France, bordering Germany. Four collection sites were investigated in different locations in the region, with variable vegetation and environment (i.e. natural or suburban). These sites were defined in earlier studies [13, 19], and EPHB2 details are demonstrated in Additional file 1: Table S1. Among these four sites, site A was defined as the control site because of the low prevalence of Lyme borreliosis in this area [13, 19]. From April 2013 to November 2016, 4354 questing nymphs were field collected by dragging a white flannel flag (1 1 m) over low vegetation. Individuals and whole blood samples Between May 2010 and July 2016, EDTA blood samples from 575 individuals were sent to the medical microbiology laboratory of the University or college Private hospitals of Strasbourg for analysis by PCR. From May 2010 to July 2012, these individuals were recruited for the study GSK J1 of HGA [20]. The inclusion criteria were (i) fever or another sign presumed to be related to a tick bite happening within a maximum of 4 weeks before the beginning of symptoms; (ii) individuals exposed to tick bites with fever and at least one haematological abnormality or irregular liver function checks; and (iii) individuals with a minumum of one haematological abnormality or irregular liver function checks happening maximum 4 weeks after a proven tick bite. At the time of recruitment, individuals were examined by infectious disease.